

Alfuzosin

Class: Alpha₁ Blocker.

Indications: Treatment of the functional symptoms of benign prostatic hyperplasia (BPH).

Available dosage form in the hospital: ALFUZOSIN 10MG M/R TABLET

Trade Names:

Dosage

-Benign prostatic hyperplasia (BPH): Oral: 10 mg once daily.

-Ureteral stones, expulsion (unlabeled use): Oral: 10 mg once daily, discontinue after successful expulsion (average time to expulsion 1-2 weeks) (Agrawal, 2009; Ahmed, 2010; Gurbuz, 2011). **Note:** Patients with stones >10 mm were excluded from studies.

Renal Impairment:

Bioavailability and maximum serum concentrations are increased by ~50% with mild (Cl_{cr} 60-80 mL/minute), moderate (Cl_{cr} 30-59 mL/minute), or severe (Cl_{cr} <30 mL/minute) renal impairment.

Note: Safety data is limited in patients with severe renal impairment (Cl_{cr} <30 mL/minute). Use with caution.

Hepatic Impairment:

-Mild hepatic impairment: Use has not been studied; use caution.

-Moderate or severe hepatic impairment (Child-Pugh class B or C): Clearance is decreased $\frac{1}{3}$ to $\frac{1}{4}$ and serum concentration is increased three- to fourfold; use is contraindicated.

Common side effect: 1% to 10%

Central nervous system: Dizziness, fatigue, headache, pain.

Gastrointestinal: Abdominal pain, constipation, dyspepsia, nausea

Genitourinary: Impotence

Respiratory: Upper respiratory tract infection, bronchitis, pharyngitis, sinusitis

Pregnancy Risk Factor: B